2030, Biosimilars and Pharmaceutical Companies

Biopharmaceuticals contributing to manufacturing outsourcing trend

European Pharmaceutical Review

APRIL 3, 2024

Research by Roots Analysis predicts the pharmaceutical contract manufacturing market will value $140 billion by 2030. percent between 2022-2030. The report noted that there has been “considerable” merger and acquisition activity in recent years within the pharmaceutical contract manufacturing market.

Pharmaceutical Companies

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Compounding

Pharma sector gears up for Budget 2024-25; Calls for innovation and regulatory reforms

Express Pharma

JULY 21, 2024

Recognising the pharmaceutical industry’s substantial contribution to India’s exports, we eagerly anticipate schemes that provide fiscal incentives to encourage such exports. Indian Pharmaceutical sector trying to reach the USD 130 Billion target by 2030.

Sandoz targets barriers to biosimilar accessibility with latest initiative

Pharmaceutical Technology

JUNE 15, 2023

Generic and biosimilar pharmaceutical company and Novartis subsidiary Sandoz announced its plan to accelerate patient access to biosimilars. In a 15 June statement, Sandoz said that it hoped the Act4Biosimilars action plan will provide actionable solutions to overcome barriers preventing patient access to biosimilars.

International life sciences regulations: How CROs, CMOs, and CDMOs are primed for advantage

Express Pharma

OCTOBER 16, 2024

billion by 2030 (2). Similarly, India’s pharmaceutical contract manufacturing market is expected to increase at a CAGR of 14.67 Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. per cent, hitting $44.63

‘Insulin for muscle’ and the AI platform behind it, with Hanadie Yousef

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

2nd Translational Digital Pathology & AI Summit

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

After rebuffing Biogen, Sage pairs off with Supernus

pharmaphorum

JUNE 16, 2025

Skip to main content Monday 16 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars

Pharma sector awaits Budget 2024 for innovation boost and regulatory reforms

Express Pharma

JULY 15, 2024

This would encourage pharmaceutical companies to enhance their R&D efforts, bolstering India’s status as a global leader in innovative healthcare solutions. The government should incentivise research and development (R&D) by increasing the weighted tax deduction for R&D expenditure from 100 per cent to 200 per cent.

Medical Records

Medical Records Biosimilars Pharmaceutical Companies Pharmaceutical Companies

The next frontier: Global leadership in biopharma

Express Pharma

JULY 10, 2024

Brimming with potential As per an Invest India report of 2023, the Indian Bioeconomy, valued at $137 billion in 2023, is targeted to reach $150 billion by 2025 and $300 billion by 2030. IBER Report 2023 divulges, “The biopharma vaccines (non-COVID alone) market makes a significant daily contribution of approximately $38 million. billion.”

Vaccines

Vaccines Drug Development Process Improvement Biosimilars

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

pharmaphorum

NOVEMBER 10, 2022

We can talk all the time, Montserrat said, but now is the time for action: early diagnosis, access to the best treatments, innovation, in addition to protection of intellectual property (IP), and after that biosimilars and generics. With 90% of adolescents that should be vaccinated by 2030, Luppi deems it an opportunity.

Vaccines

Vaccines Labelling Biosimilars Pharmaceutical Companies

Bio-Thera and Tabuk partner for Stelara biosimilar in Saudi Arabia

Pharmaceutical Business Review

DECEMBER 26, 2024

Tabuk Pharmaceuticals CEO Ismail Shehada said: “We are excited to announce our partnership with Bio-Thera that will enable us to deliver unique and specialised health solutions aimed at enhancing the well-being of people inSaudi Arabia.

Pharmacist Digest

Biopharmaceuticals contributing to manufacturing outsourcing trend

Pharma sector gears up for Budget 2024-25; Calls for innovation and regulatory reforms

Trending Sources

Sandoz targets barriers to biosimilar accessibility with latest initiative

International life sciences regulations: How CROs, CMOs, and CDMOs are primed for advantage

‘Insulin for muscle’ and the AI platform behind it, with Hanadie Yousef

2nd Translational Digital Pathology & AI Summit

After rebuffing Biogen, Sage pairs off with Supernus

Pharma sector awaits Budget 2024 for innovation boost and regulatory reforms

The next frontier: Global leadership in biopharma

Economist Impact: World Cancer Series – pharmaphorum in attendance, day one (part ii)

Bio-Thera and Tabuk partner for Stelara biosimilar in Saudi Arabia

Stay Connected